APP Group's Move Towards Sustainable Leadership in the Pulp and Tissue Paper Sector in South Korea

2024-11-22 APP Group HaiPress

JAKARTA,Indonesia,Nov. 21,2024 -- APP Group has expanded into the South Korean market by acquiring 100% of MSS Holdings,the majority shareholder ofSsangyong C&B,known for popular tissue brands like CODI and Monalisa.

This strategic acquisition,valued at approximately 400 billion won (around $296 million),underscores APP Group's commitment to growth in Asia and its leadership in driving sustainability,particularly in South Korea.

Korea is currently the fifth largest market size for paper,pulp,and paperboard regionally. Its pulp and paper sector are projected to grow at a CAGR of 5.20% from 2023 to 2028. With this acquisition,MSS is expected to benefit from APP's operations expertise & global network as an established company in the global market. MSS is expected to synergize and enhance its efficiency and overall cost competitiveness.

Alternatively for APP Group,this opportunity is a good chance to have exposure in the Korean tissue and hygiene market,with instant access to well-known consumer brands and a nationwide domestic sales network as well as moving towards sustainable leadership in South Korea.

"We are delighted to welcome MSS to APP and with APP's global expertise,MSS can offer APP's global high-quality tissue and hygiene products to Korea,providing Korean consumers with more innovative choices at competitive prices," said Nishant Grover,CEO of Tissues International at APP.

APP Group is known as the fourth largest pulp production in the world and is known for their diverse pulp-based products such as tissue,paper and packaging sold in over 150 countries. By acquiring Ssangyong C&B,APP Group is poised to bring its vision of sustainability to South Korea,fostering partnerships and collaborations that promote responsible sourcing and innovative solutions in the industry.

About APP Group

APP is a leading pulp,paper,and forestry company based in Indonesia,supplying high-quality tissue,packaging,and paper to over 150 countries. With operations in Indonesia and China,we prioritize sustainability,ethical practices,and the well-being of our employees,society,and the environment. Our Sustainability Roadmap Vision 2030,aligned with ESG principles,guides our efforts in environmental protection,community support,biodiversity preservation,and carbon neutrality.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map